John C. Bloom holds a B.S. degree in biology from the Univ of Pittsburgh and doctorates in veterinary medicine and hematology/oncology from the Univ of Pennsylvania. He completed his postdoc training at Jefferson Medical College in hematology/oncology and served on the Faculty of the Univ of Pennsylvania School of Veterinary Medicine as Chief, Clinical Laboratory Medicine, before joining Smith Kline & French Labs as Assoc Dir of Pathology. He later joined Lilly Research Laboratories as Head, Clinical Pathology, in the Toxicology Division, and subsequently moved to the Medical Division, where he established the depts of Clinical Laboratory Medicine, Experimental Medicine and Clinical Diagnostic Services. As Distinguished Medical Fellow, Diagnostic Read more
John C. Bloom holds a B.S. degree in biology from the Univ of Pittsburgh and doctorates in veterinary medicine and hematology/oncology from the Univ of Pennsylvania. He completed his postdoc training at Jefferson Medical College in hematology/oncology and served on the Faculty of the Univ of Pennsylvania School of Veterinary Medicine as Chief, Clinical Laboratory Medicine, before joining Smith Kline & French Labs as Assoc Dir of Pathology. He later joined Lilly Research Laboratories as Head, Clinical Pathology, in the Toxicology Division, and subsequently moved to the Medical Division, where he established the depts of Clinical Laboratory Medicine, Experimental Medicine and Clinical Diagnostic Services. As Distinguished Medical Fellow, Diagnostic and Experimental Medicine, he was responsible for routine lab, ECG, imaging and specimen banking support for global clinical development; and novel clinical biomarker discovery, validation and application in the Div of Translational Medicine and Pharmacogenomics. In that role he also served as executive sponsor for the development of Lilly’s diagnostic strategy, as part of the Co’s broader Tailored Therapeutics Initiative. Dr. Bloom is a past president of the American Society for Veterinary Clinical Pathology; has authored several manuscripts, chapters, reviews and texts on toxicology and clinical biomarkers in drug development; and served on committees sponsored by the National Academy of Sciences, Institute of Medicine, Society of Toxicologic Pathology and PhRMA. Upon his retirement from Lilly in 2009 he established Bloom Consulting Services and has been appointed Consultant, Office of the Center Director, FDA. In the latter capacity he serves on Drug Advisory Committees and special FDA/NIH project assignments. Dr. Bloom serves on several Scientific Advisory Committees for biopharm, diagnostic and biopharm services companies and holds adjunct academic appointments at the Univ of Pennsylvania and Purdue University.
